clinical trial · NCT05431387
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
Achieve Life Sciences·phase2·completed·n = 160
VapingE-Cig UsecytisiniclinePlaceboBehavioral support
brief summary
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
started
Jul 13, 2022
primary completion
Feb 28, 2023
completion
Feb 28, 2023
last updated
Jan 14, 2026
official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adults Using Nicotine-containing E-cigarettes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol